Objective-Liver X receptors (LXRs) modulate cholesterol and fatty acid homeostasis as well as inflammation. This study aims to decipher the role of LXRs in the regulation of polyunsaturated fatty acid (PUFA) synthesis in macrophages in the context of atherosclerosis. Approach and Results-Transcriptomic analysis in human monocytes and macrophages was used to identify putative LXR target genes among enzymes involved in PUFA biosynthesis. In parallel, the consequences of LXR activation or LXR invalidation on PUFA synthesis and distribution were determined. Finally, we investigated the impact of LXR activation on PUFA metabolism in vivo in apolipoprotein E-deficient mice. mRNA levels of acyl-CoA synthase longchain family member 3, fatty acid desaturases 1 and 2, and fatty acid elongase 5 were significantly increased in human macrophages after LXR agonist treatment, involving both direct and sterol responsive element binding protein-1-dependent mechanisms. Subsequently, pharmacological LXR agonist increased long chain PUFA synthesis and enhanced arachidonic acid content in the phospholipids of human macrophages. Increased fatty acid desaturases 1 and 2 and acyl-CoA synthase long-chain family member 3 mRNA levels as well as increased arachidonic acid to linoleic acid and docosahexaenoic acid to eicosapentaenoic acid ratios were also found in atheroma plaque and peritoneal foam cells from LXR agonist-treated mice. By contrast, murine LXR-deficient macrophages displayed reduced expression of fatty acid elongase 5, acyl-CoA synthase long-chain family member 3 and fatty acid desaturases 1, as well as decreased cellular levels of docosahexaenoic acid and arachidonic acid. 
L iver X receptors (LXRs) α and β (NR1H3 and NR1H2, respectively) are nuclear receptors activated by oxidized derivatives of cholesterol and by intermediates of the cholesterol synthesis pathway. 1, 2 LXRs are involved in the regulation of cholesterol homeostasis, in the control of inflammation and the innate immune response. 3, 4 Notably, LXR activation stimulates the reverse cholesterol transport pathway through the coordinated activation of cellular cholesterol efflux, plasma cholesterol transport, and finally hepatic and intestinal cholesterol excretion. Besides regulating cholesterol homeostasis, LXRs also play an important role in fatty acid metabolism because several genes of the fatty acid biosynthesis pathway such as acetyl-CoA carboxylase, fatty acid synthase (FASN), and steroyl-CoA desaturase (SCD1) have been shown as direct LXR targets. [5] [6] [7] [8] Key lipogenic transcription factors including the sterol responsive element binding protein 1c (SREBP1), carbohydrate-response element-binding protein, and peroxisome proliferator activated receptor γ are also directly regulated by LXR. [9] [10] [11] Accordingly, pharmacological activation of LXRs results in a marked stimulation of lipogenesis in vivo, particularly in the liver. As a consequence, the administration of a synthetic LXR agonist such as T0901317 in mice induces a massive increase in the synthesis of fatty acids and triglycerides in the liver, resulting in hepatomegaly and steatosis as well as increased plasma triglyceride levels. 8, 12 This hepatic steatosis, driven mainly by the LXRα isoform, is a major undesirable side effect which has to date limited the therapeutic development of synthetic LXR agonists. 13 Although the impact on the liver is the most dramatic side effect, LXR activation also induces lipogenesis and triglyceride accumulation in other cells/tissues such as the pancreas and skeletal muscle cells. 14, 15 In adipocytes, the role of LXRs in controlling lipogenesis seems to be more complex with recent studies suggesting that LXRs regulate fatty acid synthesis in subcutaneous and visceral adipose tissues in different ways. 16 At this stage, the impact of LXRs on lipogenesis in macrophages has been less documented. Nevertheless, LXR activation in macrophages is known to increase the expression of lipogenic genes such as SREBP1 and SCDs. 17, 18 From a qualitative standpoint, LXR activation has been reported to induce the preferential formation of C16 and C18 monounsaturated fatty acids (MUFAs) belonging to the n-7 or n-9 families, resulting in an increased MUFA/saturated fatty acid ratio in the liver. This LXR-driven synthesis of MUFAs may be important to prevent the lipotoxicity induced by the intracellular accumulation of fatty acids. 19 Interestingly, some of the fatty acids whose synthesis is stimulated by LXRs such as 9Z-palmitoleic acid possess specific insulin-sensitizing and anti-inflammatory properties. 2, 20 In contrast to MUFAs, much less is known about the role of LXRs on long chain polyunsaturated fatty acid (PUFA) metabolism. Although it has been demonstrated that some PUFAs such as arachidonic acid (AA; C20:4 n-6) or eicosapentaenoic acid (EPA; C20:5 n-3) act as LXR antagonists, 21, 22 it is unknown whether LXRs are reciprocally able to interfere with PUFA metabolism and to modulate the synthesis of these molecules from their C18 precursors. Nevertheless, there is some evidence in support of such roles for LXRs. Indeed, it has been shown that LXR agonists increased AA levels in vitro in hepatoma cells. 23 A study from our group showed that LXR could increase the total amount of AA in polar lipids in human macrophages. 24 Finally, it has been demonstrated that nuclear receptor corepressor (NCoR) deficiency in mice results in the derepression of long chain ω-3 fatty acid synthesis probably through a LXR-dependent mechanism. 25 The aim of this present work was therefore to investigate whether LXR activation could directly affect PUFA synthesis in macrophages in vitro and in vivo. Primary macrophages were treated with LXR agonists and mRNA levels of genes involved in PUFA synthesis were evaluated in parallel to fatty acid levels and their distribution. We show here that in macrophages, LXRs control in a coordinated manner the enzymes involved in the conversion of C18 precursors into long chain n-3 and n-6 PUFAs; this leads to increased PUFA synthesis and PUFA levels in LXR-agonist stimulated macrophages. Moreover, we show for the first time the relevance of this pathway in vivo in atherosclerotic arteries from apolipoprotein E-deficient (ApoE −/− ) mice.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

Activation of LXRs Results in the Induction of Genes Involved in PUFA Synthesis in Human Macrophages
Transcriptomic analysis was performed in human primary monocytes from 2 healthy donors treated or not with the synthetic LXR agonist T0901317 at 10 µmol/L for 48 hours. As expected, LXR activation resulted in the marked induction of well-established LXR target genes involved in saturated fatty acid and MUFA synthesis such as acetyl-CoA carboxylase, FASN, and SCD1. LXR activation also induced the master transcriptional regulator of lipogenesis, SREBP1 ( Figure 1A ). Interestingly, PUFA synthesis was also affected as depicted by the significant induction of ∆5 and ∆6 desaturases (fatty acid desaturase 1 [FADS1] and FADS2, respectively) after LXR agonist treatment as well as the induction of acyl-CoA synthase long-chain family member 3 (ACSL3) and the fatty acid elongase 5 (ELOVL5). The acyl-CoA synthase long-chain family member 4 (ACSL4) was significantly induced in 1 of the 2 donors.
Microarray data were further supported by real-time polymerase chain reaction analysis in primary human macrophages. As shown in Figure 1B , treatment with T0901317 at 1 µmol/L for 24 hours resulted in a marked induction of FADS1 and FADS2 mRNA levels (≈30-fold increases; P<0.05) as compared with dimethyl sulfoxide controls. ELOVL5 and ACSL3 were also significantly induced by LXR agonist treatment (10-and 5-fold increases, respectively; P<0.05). In contrast, no significant induction of ACSL4 was observed (data not shown). Similar results were obtained with macrophages from distinct healthy donors. Treatment with different concentrations of T0901317 induced a dose-dependent increase of mRNA levels for all the genes with a maximal induction at 10 µmol/L ( Figure I in the online-only Data Supplement). In order to determine whether the T0901317-mediated induction of these genes was mediated by a specific LXR isoform, differentiated human macrophages 
LXRs Regulate Genes Involved in PUFA Synthesis Through Both Direct and SREBP1-Dependent Manner
LXRs are known to regulate genes involved in fatty acid synthesis through both direct and indirect mechanisms via the activation of the lipogenic transcription factor SREBP1. In order to evaluate the possible contribution of SREBP1, differentiated human macrophages were transfected with negative or SREBP1 small interfering RNAs and, 48 hours later, were treated with T0901317 at 1 µmol/L or dimethyl sulfoxide for an additional 24-hour period. SREBP1 knockdown significantly reduced mRNA levels of all the target genes under T0901317 conditions indicating that SREBP1 contributed in part to the LXR-mediated induction of FADS1, FADS2, ACSL3, and ELOVL5 ( Figure 2A) . In a further step, we took advantage of the unique properties of desmosterol, which is a physiological LXR agonist as well as an inhibitor of SREBP1 proteolytic cleavage and its subsequent nuclear processing. 26 As shown in Figure 2B , desmosterol treatment strongly inhibited FADS1 and FADS2 expression and tended to increase ELOVL5 and ACSL3 mRNA levels. As expected, we observed that desmosterol treatment significantly increased mRNA levels of ABCA1 or lysophosphatidylcholine acyl transferase 3 (LPCAT3), which are known to be direct LXR target genes ( Figure 2B and Figure III in the online-only Data Supplement). Interestingly, desmosterol treatment also increased SCD1 but not FASN mRNA levels.
To further delineate the underlying mechanism with regards to the desmosterol-dependent inhibition of FADS1/FADS2, we treated vehicle-treated or LXR agonist-treated human primary macrophages along with the translation inhibitor cycloheximide. Cycloheximide treatment totally abolished the LXR response of FADS1 and FADS2 ( Figure IV in the online-only Data Supplement). The picture was different with ACSL3 and ELOVL5 as induction of their expression was maintained in T0901317-treated macrophages in the presence of cycloheximide. These data therefore suggest that FADS1 and FADS2 are mainly regulated through the LXR-SREBP1 cascade, whereas ACSL3 and ELOVL5 could also be regulated directly by LXRs. A functional LXRE has been previously reported in the ACSL3 promoter. 27 Interestingly, a recent Chip-sequencing survey performed in human macrophages showed a potential LXR binding site in ELOVL5 gene ≈10 000 bp upstream from the transcription start site. 28 To address the functionality of this potential LXRE in the ELOVL5 gene, the corresponding element (DR4 element: GGGTAAttccCGGGCA) was cloned upstream of a thymidine kinase promoter-luciferase vector or added to the proximal ELOVL5 promoter (−1000 bp) cloned into a pGL3 luciferase reporter vector. In both cases the activity of the promoters was significantly increased in HEK293T (human embryonic kidney 293) cells cotransfected with LXRα and RXRα expression vectors and treated with T0901317 ( Figure 2C ). These inductions were abolished by mutation of the LXR element ( Figure 2C ).
LXR Activation Increases Arachidonate Levels in Polar Lipids in Primary Human Macrophages
To determine whether the changes observed at the transcriptional level translated into modifications of the fatty acid profile, total fatty acid composition of human macrophages treated or not with LXR agonist was assessed by gas chromatography-mass spectrometry. As shown in Figure 3A and in accordance with the induction of FASN, acetyl-CoA carboxylase, and SCD1, LXR activation induced significant increases in the net amount and relative proportion of C16 and C18 MUFAs. Interestingly, an increase in the total amount of AA was also observed. Further analysis of the fatty acid composition of neutral lipids (triglycerides and cholesteryl esters) and polar lipids (glycerophospholipids and sphingolipids) revealed that the increased AA content primarily affected the polar lipid fraction ( Figure 3B and 3C ).
To further characterize the fractions containing AA, the main molecular species present in the polar lipid fraction (sphingolipids, phosphatidylcholines, and phosphatidylethanolamines) were analyzed by liquid chromatography-mass spectrometry. 2 As shown in Figure V in the online-only Data Supplement, treatment with T0901317 induced an increase in phosphatidylcholines containing MUFAs at the expense of species containing saturated fatty acids. An enrichment of molecules containing PUFAs including AA was also observed. Similar, although less pronounced changes were also present in the phosphatidylethanolamines (Figure VB in the onlineonly Data Supplement). No significant amounts of PUFAs were found in the sphingolipid fraction (data not shown).
LXR Deficiency Alters PUFA Metabolism in Mouse Macrophages
To assess the intrinsic function of LXRs in the regulation of PUFA metabolism in the absence of pharmacological activation, bone marrow-derived macrophages were prepared from WT or Lxrαβ-deficient (Lxrαβ enzymes (Elovl5, Acsl3, and Fads1) involved PUFA metabolism ( Figure 4A ), significant decrease of AA and docosahexaenoic acid (DHA) content ( Figure 4B ) along with a significant reduction in the proportion of PUFA in phosphatidylcholines ( Figure 4C ). As previously reported, 17 we observed here that LXR deficiency could also derepressed some target genes such as Abca1 or Abcg1 ( Figure VI in the online-only Data Supplement), Interestingly a similar derepression was also retrieved for genes involved in fatty acid metabolism such as Scd2 ( Figure VI in the online-only Data Supplement).
LXR Activation Promotes the Synthesis of n-6 and n-3 PUFAs From C18 Substrates
To determine whether the increased AA levels were because of increased uptake, decreased catabolism, or activation of synthesis, we directly measured the synthesis of AA in human macrophages at the basal state or after stimulation by LXR agonists (T0901317 or desmosterol). Primary macrophages were pretreated for 24 hours with T0901317 at 1 µmol/L or desmosterol at 10 µmol/ and then incubated for 24 hours in the presence of a tracer dose of deuterated linoleic acid (LA; C18:2 n-6) to measure its conversion into deuterated AA. The conversion rate was low in nonstimulated macrophages as deuterated AA represented <5% of the total deuterated molecules ( Figure 5A ). In contrast, the conversion was dramatically higher in LXR agonist-treated macrophages, with deuterated AA levels corresponding to ≈25% of the total deuterated molecules. In accordance with the previous transcriptomic data, treatment with desmosterol induced no stimulation and even tended to decrease the biosynthesis of AA.
Because the enzymatic steps for the synthesis of long-chain n-3 and n-6 PUFAs are identical, we repeated the experiment using deuterated C18-3 n-3 as the substrate. As shown in Figure 5B , LXR agonist treatment induced the formation of n-3 long chain PUFAs, notably C20:4 n-3 and docosapentaenoic acid (C22:5 n-3). We could not detect the formation of DHA which requires a specific pathway for its synthesis.
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LXR Activates PUFA Synthesis In Vivo in Atherosclerotic Arteries and Foam Cells
To address the pathophysiological relevance of our in vitro observations, we studied the impact of LXR agonists on the synthesis of PUFAs in atheroma plaque in vivo. To this end, Figure 5 . Liver X receptor agonist treatment directly promotes n-6 and n-3 polyunsaturated fatty acid (PUFA) biosynthesis in human macrophages. Human macrophages were pretreated with vehicle or T0901317 (1 µmol/L) or desmosterol (10 µmol/L) for 24 hours and then incubated with deuterated n-6 linoleic acid and n-3 linolenic acid for 24 hours before fatty acid analysis by gas chromatography-mass spectrometry. A, Relative amount of deuterated arachidonic acid as compared with total deuterated fatty acids; B, relative amounts of n-3 deuterated PUFAs as compared with total deuterated fatty acids. Values are mean±SD of 3 independent experiments. *Significantly different from dimethyl sulfoxide conditions. P<0.05, Mann-Whitney test. ND indicates not detectable.
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−/− mice, treated or not with an LXR agonist (T0901317), were fed a Western type diet for 8 weeks. This well-described approach leads to the development of atheroma in the aorta and aortic valves along with the development of massive lesions in the brachiocephalic and in the left common carotid arteries. Moreover, LXR agonists are known to exert atheroprotective effects in this model. 30 Left common carotid and brachiocephalic arteries were harvested and cleaned under a dissecting microscope and used for transcriptomic and fatty acid analysis, respectively. Analysis of the total fatty acid profile revealed an increase in the proportion of MUFAs including 9Z-palmitoleic acid (C16:1 n-7). A similar, although not statistically significant, trend was also observed for several PUFAs such as 22:6 n-3, C22:4 n-6, and C20:4 n-6 ( Figure 6A ). The AA:LA ratio, which is considered a reliable marker of desaturase activities and AA biosynthesis, was significantly increased in LXR-treated mice. About n-3 fatty acids, the C18 precursor α-linolenic acid was barely detectable in the arteries but the DHA/EPA ratio was significantly higher in LXR agonist-treated mice suggesting an increased conversion of EPA to DHA.
About the enzymes involved in PUFA biosynthesis, significant inductions of Fads1, Fads2, and Acsl3 mRNA levels were observed in the arteries from T0901317-treated mice ( Figure 6B ). However, in contrast to our in vitro observations in human macrophages, we did not find any significant increase in Elovl5 mRNA levels in LXR agonist-treated mice. Genes involved in MUFA synthesis such as Srebp1, Fasn, Scd1, and Scd2 were also significantly induced ( Figure 
Discussion
In the present study, we demonstrated that activation of LXRs in macrophages induced the expression of all key enzymes of the PUFA synthesis in a coordinated manner. Consistent with these transcriptomic data, we found an increase in the rate of PUFA synthesis from either n-6 or n-3 precursors as well as the enrichment of phospholipids with AA. Reciprocally, LXR deficiency in mouse macrophages resulted in decrease expression of main enzymes involved in PUFA metabolism, as well as a reduced AA and DHA content. Noteworthy, in vitro data were further confirmed in vivo in mouse in atherosclerotic arteries and foam cells as we showed that LXR activation B A Figure 6 . Liver X receptor agonist treatment activate gene involved in polyunsaturated fatty acid (PUFA) biosynthesis and modulates PUFA composition of atherosclerotic arteries. ApoE −/− mice were fed a Western type diet containing either T0901317 (10 mg/kg per day) or vehicle for 8 weeks. Brachiocephalic and left common carotid arteries were collected to evaluate fatty acid composition and relative mRNA levels of genes of interest, respectively. A, Total amounts of individual fatty acids were determined by gas chromatography-mass spectrometry. Values were normalized to 1.00 for mice fed the control diet. B, mRNA levels of target genes were determined by real-time polymerase chain reaction. Each bar represents the mean±SD of 6 mice. *P<0.05 vs mice fed the control diet, Mann-Whitney test.
modulates in situ the PUFA composition and increases the expression of genes that control PUFA synthesis.
Synthesis of PUFA is a multistep process requiring the initial activation of the substrate fatty acid into an acyl-CoA by an acyl-CoA synthase and the successive actions of elongases and desaturases ( Figure 7) . Interestingly, LXR activation in human macrophages resulted in the coordinated induction of these 3 classes of enzymes. Although there are at least 5 long chain fatty acyl CoA synthases, they display differential tissue distribution and specificity toward fatty acids. Interestingly, ACSL3 exhibits a preference for C18-C20 PUFAs over saturated and monounsaturated fatty acids. 32 The regulation of ACSL3 by LXR has been described in placental trophoblast cells 27 but to our knowledge no data on ACSL3 regulation by LXR in macrophages has been reported to date. As for ACSLs, several fatty acid elongases are present in mammals with different specificities. Data obtained in Elovl5 −/− mice indicate that ELOVL5 is required for the synthesis of long chain n-3 and n-6 PUFA since Elovl5 −/− mice accumulate n-6 and n-3 C18 precursors in their tissues at the expense of the downstream products AA and DHA. 33 Indirect regulation of ELOVL5 by LXRα through a SREBP1-dependent pathway has been reported in mouse liver. 23 We showed here that ELOVL5 is also a direct LXR target gene in human macrophages and that a potential LXRE identified previously by Chip-sequencing is fully functional. 28 In contrast to ACSLs and elongases, no redundancy exists for the ∆5 and ∆6 desaturases (FADS1 and FADS2), which are unique in the human genome and are absolutely required for PUFA synthesis. 34 Moreover, ∆6 desaturation has been described as the limiting step for long chain PUFA synthesis. 34 It has been demonstrated that FADS1 and FADS2 are regulated by peroxisome proliferator activated receptors and by SREBP1. 35, 36 In accordance with these data, the results of the present study strongly suggest that the T0901317-mediated induction of FADS1 and FADS2 at least in human macrophages is fully dependent on SREBP1 because desmosterol, an LXR agonist, but also an inhibitor of the SREBP1 cleavage, strongly repressed FADS1 and FADS2 expression in vitro.
Although the role of LXRs in MUFA synthesis is well established, there are only few data on the impact of LXRs in PUFA metabolism. Nevertheless, some interactions between PUFAand LXR-regulated pathways have been suggested. Indeed, several long chain PUFAs such as AA, EPA, and DHA are known to be potent LXR antagonists and inhibitors of SREBP1 transcription. 21, 22 This mechanism probably accounts for the ability of unsaturated fatty acid to inhibit fatty acid and triglyceride synthesis. Reciprocally, it has been recently demonstrated that LXRs modulate PUFA distribution in macrophages and liver through the induction of LPCAT3. 24, 37 In human primary macrophages, LPCAT3 preferentially promoted the incorporation of AA at the sn-2 position of lysophosphatidylcholines resulting in an enrichment of phosphatidylcholines with AA after LXR agonist treatment. 24 Interestingly, when LPCAT3 was inhibited, LXR agonists triggered an increase in AA levels in the neutral lipid fraction, suggesting an increased availability of AA in the cells that was independent of LPCAT3. Recently, Li et al 25 reported that specific deletion of NCoR in mouse macrophages resulted in the derepression of several enzymes involved in PUFA synthesis such as ELOVL5 and FADS2 in a LXR-dependent manner. This was associated with increased levels of n-3 long chain PUFAs such as EPA and DHA. Although most of our data are in accordance with this study, it is worth noting some important differences. First, Li et al did not activate LXR directly with specific agonists, but they observed a derepression of some LXR target genes after NCoR deletion in macrophages. Second, the levels of long chain n-6 PUFA such as AA were not assessed in this study; however, because the same enzymes are required for long chain n-3 and n-6 PUFA synthesis, it would be of high interest to investigate whether NCoR deficiency in mouse macrophage also increases the level of AA in parallel to DHA and EPA.
Although it is reported here that the activation of PUFA synthesis by LXR agonists involved the direct regulation of some target genes, it was also highly dependent on the activation of SREBP1, an indirect pathway that is particularly relevant for FADS1 and FADS2. Thus, desmosterol, an inhibitor of SREBP1-cleavage, repressed the expression of both desaturases and does not stimulate the synthesis of AA. Importantly, this did not occur with the synthetic LXR agonist T0901317, thus highlighting a major difference in the biological activity of nonsteroidal versus steroidal LXR agonists. In contrast, desmosterol ) and sterol responsive element binding protein-1c (SREBP1c)-dependent regulation. Interestingly, LXR activation also increased lysophosphatidylcholine acyl transferase 3 (LPCAT3), which promotes the preferential incorporation of PUFAs into glycerophospholipids. n-6 pathway is shown as example. A similar pathway is used for n-3 fatty acids to synthesize eicosapentaenoic acid (EPA) from linolenic acid. However, docosahexaenoic acid synthesis from EPA requires sequential elongation/delta 6 desaturation followed by 1 cycle of β oxidation (Sprecher pathway). AA indicates arachidonic acid.
retains the ability to stimulate the synthesis of MUFA such as the insulin sensitizer 9Z-palmitoleic acid by activating SCDs as described recently 2 and as we found in the present study. In contrast to what was observed in macrophages, in vivo treatment of ApoE −/− mice did not upregulate PUFA metabolism in the liver, The mechanisms underlying these differential effects are unclear; it could be related either to the specific metabolic context in which LXR target genes are already highly induced in the liver (ApoE −/− mice under Western type diet) or to a negative feedback loop in link with the massive fatty acid accumulation in the liver of LXR agonist-treated mice.
Finally, LXR regulation of PUFA metabolism in macrophages is likely to have significant biological consequences because these molecules and their oxygenated derivatives are potent biological mediators with both pro-and anti-inflammatory properties. We previously observed that the LXR-mediated induction of LPCAT3 primed human macrophages for subsequent eicosanoid secretion by increasing the pool of AA in the phospholipid fraction. In contrast, derepression of n-3 PUFA synthesis by NCoR deficiency in macrophages resulted in an anti-inflammatory, insulin-sensitive phenotype in mice. 25 We observed in the present study that LXR agonist treatment of ApoE −/− mice led to significant changes of the PUFA profile in atherosclerotic arteries with increases in both the AA/LA and the DHA/EPA ratio and was associated with the decreased expression of proinflammatory genes such as Cox2 and Il1β. These data therefore suggest that local production of PUFA and derived lipid mediators triggered by LXR within the atheroma plaque could affect inflammation and atherosclerosis development, a hypothesis that deserves further investigation. Nevertheless, the activation of specific targets in macrophages within the atheroma plaque is essential for the atheroprotective effect of LXR agonists. 38, 39 Furthermore, PUFA and their oxidized derivatives are known to be involved in the regulation of the inflammatory response and in the development of atherosclerosis. 40, 41 Because LXRs are able to promote the synthesis of long chain PUFA from both n-3 and n-6 substrates, their overall impact is likely to be dependent on the quality and the relative abundance of the initial n-6 or n-3 substrates. Interestingly, although some interspecies differences were previously reported on LXR target genes, PUFA metabolism seems to be regulated in a similar way by LXR in humans and mice. Nevertheless, it is worth to note that DHA synthesis, as compared with AA, seems to be preferentially regulated by LXR in mice, an effect we did not retrieve in vitro in human macrophages. Finally, our data bring some support to the hypothesis that the antiatherogenic activity of LXR agonists could be directly related to their lipogenic activity in the vascular wall. 42, 43 Liver X receptors are oxysterol-activated nuclear receptors that control different pathways such as cholesterol and fatty acid metabolism or inflammation. We demonstrate that in macrophages, liver X receptors coordinately regulate the enzymes responsible for the synthesis of long chain polyunsaturated fatty acids, including activation into acylCoA, elongation, and formation of additional double bonds. As a consequence, liver X receptor activation increases the amounts of n-3 and n-6 long chain fatty acid such as docosahexaenoic acid and arachidonic acid in macrophages. Importantly, we observed that this activation of polyunsaturated fatty acid synthesis occurred in situ in the atheroma plaque in mouse. Because PUFA and their oxidized derivatives are known to be involved in the regulation of the inflammatory response and in the development of atherosclerosis, our data bring some support to the hypothesis that the antiatherogenic activity of liver X receptor agonists could be directly related to their lipogenic activity in the vascular wall.
Significance
